Mountain Valley MD Holdings Inc. announced it has contracted Camargo Pharmaceutical Services, LLC (Camargo) to provide regulatory consulting services to support MVMD's pursuit of U.S. Food and Drug Administration (FDA) approval of its novel IvectosolTM rapid dissolve oral format. Camargo is recognized as one of the most experienced global organizations who specialize in drug and combination device product development and approval utilizing the regulatory pathway provided for in Section 505(b)(2) of the US Federal Food, Drug, and Cosmetic Act. Over the last decade, Camargo has established a leading track record with 505(b)(2) investigational new drug ("IND") and new drug applications ("NDA" preparations and submissions, including participation in more than 1,100 Agency meetings and more than 200 FDA NDA and ANDA (Abbreviated New Drug Applications) approvals. The 505(b)(2) new drug application is one of three U.S. Food and Drug Administration drug approval pathways and represents an appealing regulatory strategy by way of helping to avoid unnecessary duplication of studies already performed on a previously approved drug. The Company believes the 505(b)(2) pathway will result in a much less expensive and much faster route to approval, compared with a traditional development pathway, while creating a new, differentiated Ivermectin product with tremendous commercial value. As previously communicated, MVMD's solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity. The company's previously completed pre-clinical trial work with a third-party Contract Research Organization tested the solubilized Ivermectin via both an intramuscular injection and applied to rapid dissolve oral format with the Company's patented QuicksomeTM desiccated liposome technology compared to existing oral and subcutaneous injection solutions. The results demonstrated that the company's patented QuicksolTM solubilized Ivermectin offered superior pharmacokinetic performance across every single measure conducted, with no adverse side effects using up to 1/8th of the Ivermectin drug - a critical component that enables applications to use less of the Ivermectin drug while driving faster viral clearance.